Publications by authors named "Emeline Bacque"
Purpose: To report the results of OPAL (ClinicalTrials.gov identifier: NCT03574779) cohort A, a single-arm substudy of niraparib plus dostarlimab and bevacizumab for the treatment of advanced, platinum-resistant ovarian cancer (PROC).
Methods: Participants with PROC who received 1-2 previous lines of therapy were treated with niraparib (200 or 300 mg once daily), dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), and bevacizumab (15 mg/kg once every 3 weeks).
Objective: To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy.
Methods: PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) enrolled patients with newly diagnosed advanced OC who responded to first-line platinum-based chemotherapy. Patients were randomized (2:1) to niraparib or placebo once daily in 28-day cycles until disease progression, intolerable toxicity, or death.
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.
Cancer Chemother Pharmacol
November 2021
Article Synopsis
- The study aims to analyze how the drug niraparib behaves (pharmacokinetics) and its safety in patients with normal liver function compared to those with moderate liver impairment.
- Patients with advanced solid tumors were divided based on their liver function, and both groups received different dosages of niraparib to determine its effects.
- Results showed that patients with moderate hepatic impairment had higher drug exposure but similar safety compared to those with normal liver function, suggesting a lower starting dose of 200 mg for those with impaired liver function.